Skip to main content
Premium Trial:

Request an Annual Quote

Qlucore, Nebion to Promote Each Other's Data Analysis Products

NEW YORK (GenomeWeb News) – Bioinformatics firms Qlucore and Nebion today announced a collaboration to promote each other's data analysis products.

Under the terms of the deal, they will promote Qlucore Omics Explorer and Nebion's Genevestigator. Financial and other terms were not disclosed.

Qlucore Omics Explorer is a software program for exploring and analyzing high dimensional datasets interactively and in real time. Genevestigator is a web platform that integrates expression data and curated sample annotations, enabling the "systematic screening of the database for genes that have unique expression properties and validation of target and biomarker genes by checking how they respond to thousands of experimental conditions," the partners said.

Genevestigator originated as an academic project of the Swiss Federal Institute of Technology. Zurich-based Nebion took over development of the product in 2008 and then commercialized it.

In a statement Qlucore CEO Carl-Johan Ivarsson said that "Nebion complements the Qlucore product offering perfectly by enabling a web-based systematic screening of genes across many thousand experiments, so it makes perfect sense to work together to provide a broader solution to our clients."

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.